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Abstract. Salivary gland cancer (SGC) has a comparatively 
poor prognosis and is prone to frequent recurrence and 
metastases. Therefore, the development of more effective 
chemotherapy against SGC is desirable. The aim of the 
present study was to investigate the antitumour effects of 
valproic acid (VPA) against SGC in vitro and in vivo. Two 
human SGC cell lines (HSY and HSG cells) were used in 
the present study. The effects of VPA on the proliferation of 
SGC cells in vitro were assessed by MTT assay. Cancer cells 
treated with VPA were subjected to cell cycle analysis by flow 
cytometry. In addition, the expression levels of p21 and p27 
were examined by real-time RT-PCR to identify the mecha-
nisms of the antitumour effect of VPA on SGC. The effects 
of VPA on cancer growth in vivo were evaluated in a xeno-
graft model. VPA inhibited the proliferation of SGC cells in 
a dose-dependent manner in vitro. Degenerated cancer cells 
were observed at high concentrations of VPA. In the cell cycle 
analysis, VPA induced cell-growth inhibition and G1 arrest 
of cell cycle progression in both cancer cell lines in a time- 
and dose-dependent manner. VPA markedly upregulated the 
mRNA expression levels of both p21 and p27 in both SGC 
cell lines in a time-dependent manner. In the xenograft model 
experiment, VPA treatment markedly inhibited the growth of 
salivary gland tumours when compared with the growth of 
the untreated controls. VPA may be a valuable drug in the 
development of better therapeutic regimens for SGC.
Introduction
Salivary gland cancer (SGC) is a rare cancer type of the head 
and neck region where cancer cells form in major or minor sali-
vary glands (1-3). Generally, surgical resection is considered to 
be the most common and successful therapeutic approach for 
SGC performed today (1,4); however, SGC frequently recurs 
locally and metastasises to the regional lymph nodes and 
distant organs, which results in poor prognosis (4-6). Although 
other treatment approaches for SGC may include radiation 
therapy and chemotherapy, SGC exhibits low sensitivity to 
irradiation and chemotherapy. Therefore, the development of 
more effective chemotherapeutic drugs and strategies against 
SGC are desirable.
Cancer has long been known to be a primarily genetic 
disease initiated and progressed by alterations in genes, such 
as oncogenes and tumour suppressor genes. However, recent 
reports indicate that various types of cancers are caused by 
epigenetic changes, which are heritable changes in gene 
expression that occur without alteration in DNA sequences 
(7-9). These epigenetic changes, including DNA methylation 
and histone modifications, modify the structure of chromatin 
and affect the accessibility of regulatory proteins to DNA 
(10,11). Histone acetylation is one such epigenetic change and 
has been reported to play important roles in the initiation and 
progression of cancers (12,13). Histone deacetylation can cause 
the tightening of chromatin and can block transcriptional acti-
vation. Moreover, it is reversible and is regulated by a balance 
between the opposing activities of histone acetyltransferase 
(HAT) and histone deacetylase (HDAC). HAT is an enzyme 
that catalyses the acetylation of N-terminal lysine residues 
in histone proteins, which reduces the affinity of histone for 
DNA and increases the accessibility of transcriptional regula-
tory protein to chromatin (10). On the other hand, HDAC is 
an enzyme that catalyses the removal of acetyl groups from 
histones, and increased HDAC activities are usually associ-
ated with transcriptional repression (10).
Recently, altered HDAC activities have been shown to 
be present in many types of cancers, possibly representing 
an attractive target for cancer therapy (7-9,12,13). HDAC 
inhibitors induce cell cycle arrest and apoptosis of cancer 
cells by blocking deacetylases leading to the accumulation of 
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hyperacetylated histones and alteration of gene transcription 
(7,9,11,14,15,17,18). Various classes of HDAC inhibitors have 
been identified and are currently being tested in phase I/II 
clinical trials (12,13). Valproic acid (VPA), which is widely 
used for epilepsy and manic-depressive psychosis, has also 
recently garnered attention as a specific inhibitor of HDAC 
activity (7,19). It is known that chromatin with hyperacety-
lated core histones adopts a relaxed conformation with the 
unfolding of the associated DNA and chromatin remodelling 
during the nucleosome packing of DNA, which are key steps 
in the regulation of many genes that play crucial roles in cell 
growth and differentiation (10). VPA has been reported to 
show antitumour effects against many types of cancers such 
as acute myeloid leukaemia, breast and prostate cancers and 
head and neck squamous cell carcinomas. The objective of 
the present study was to define the biological and therapeutic 
effects of VPA in treating SGC.
Materials and methods
Valproic acid. Valproic acid sodium salt (VPA; Sigma 
Aldrich Co., St. Louis, MO, USA) was dissolved in Dulbecco's 
phosphate-buffered saline (PBS) without Ca2+ or Mg2+ (DPBS; 
Sigma Aldrich) as a stock solution. For in vitro experiments, 
the VPA stock solution was diluted with the complete culture 
medium. For in vivo experiments, the VPA stock solution was 
supplemented in drinking water.
Cell lines and cell culture. Two human SGC cell lines, HSY 
and HSG cells, were used in the present study. They are 
adenocarcinoma cell lines derived from the parotid gland and 
submandibular gland, respectively (20,21). These two cell lines 
produce tumours when subcutaneously inoculated into nude 
mice. They were maintained in Dulbecco's modified Eagle's 
medium (DMEM; Sigma Aldrich) supplemented with 10% 
fetal calf serum (FCS), 100 µg/ml streptomycin and 100 U/ml 
penicillin in a humidified atmosphere composed of 95% air 
and 5% CO2 at 37˚C.
In vitro cell proliferation assay. The proliferation of SGC 
cells treated with VPA was assessed by MTT assay. Cells were 
seeded on 96-well plates (Falcon, Franklin Lakes, NJ, USA) at 
2x103 cells/well in DMEM containing 10% FCS. Twenty-four 
hours later, cells were treated with various concentrations (0, 1, 
2, 5 and 10 mM) of VPA for 2 and 4 days. After VPA treatment, 
a 10 µl aliquot of 5 mg/ml 3-(4,5-dimethylthiazol-2-yl)-2,5-di-
phenyltetrazolium bromide (MTT) (Sigma Aldrich) was added 
to each well, and the cells were incubated for 4 h. The blue 
dye taken up by cells was dissolved in dimethyl sulphoxide, 
and the absorbance was measured with a microplate reader 
(Bio-Rad Laboratories, Hercules, CA, USA) at 540 nm. All 
assays were run in triplicate.
Mice and in vivo study. BALB/c nude mice were purchased 
from Japan CLEA Inc. (Osaka, Japan). The mice were main-
tained under pathogen-free conditions and were handled in 
accordance with the Guidelines for Animal Experimentation 
of Tokushima University. The experiments were initiated when 
the mice were 8 weeks of age and were performed as previ-
ously described (23). Five million HSY cells were inoculated 
subcutaneously into the backs of mice through 26G needles. 
Once palpable tumours were established at 1 week after the 
inoculation, VPA treatment was started by administering VPA 
(0, 0.2 and 0.4% w/v) in drinking water. The tumour volume 
and body weight of the mice were measured twice a week. 
Tumour volumes were calculated using the following formula: 
Tumour volume = 0.5 x L x W2, where L and W represent the 
largest diameter and the smallest diameter, respectively. For 
each treatment, six mice were used.
Cell cycle analysis. The cell cycle distribution was analysed 
using a fluorescence-activated cell sorter (FACS) as previously 
described (23,24). Cells grown under subconfluent conditions 
were treated with VPA (0, 2 and 5 mM). After 12 or 24 h of 
VPA treatment, cells were collected and fixed with ice-cold 
70% ethanol for 30 min and stored at 4˚C until further analysis. 
Then, cells were treated with propidium iodide (40  µg/ml) and 
RNase A (1 µg/ml) for 20 min at 37˚C. Samples were kept on 
ice, and the cell cycle analysis was completed by measuring 
the propidium iodide-stained DNA content with an Epics® 
XL-MCL cytometer (Beckman Coulter, Brea, CA, USA).
Real-time reverse transcription-polymerase chain reaction 
(RT-PCR). Cancer cells grown under subconfluent conditions 
were treated with VPA (0, 2 and 5 mM). After 24 or 48 h of 
VPA treatment, total RNA was prepared from the cells using 
Isogen® (Nippon Gene, Toyama, Japan) according to the 
manufacturer's instructions. The mRNA expression of p21 and 
p27 was examined by real-time reverse transcriptase-poly-
merase chain reaction (RT-PCR). Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH), a housekeeping gene, was used as 
an internal control. Gene-specific products were measured 
continuously by an ABI PRISM 7000 Sequence Detection 
System (Applied Biosystems) over 40 cycles. Experiments 
were performed at least three times.
Statistical analysis. All numerical data are expressed as the 
average of the values obtained ± SD. Significant differences 
between the means for the different groups were evaluated 
using one-way ANOVA, with the level of significance at 
P<0.05. All experiments were repeated two to three times, and 
similar results were obtained.
Results
Effect of VPA on the proliferation of salivary gland cancer cells 
in vitro. We examined the effect of VPA on cell morphology 
and proliferation of SGC cells in vitro. The morphology of 
cancer cells treated with 0, 2 and 5 mM of VPA for 24 h was 
evaluated. As shown in Fig. 1, the morphology of the HSY 
cells was transformed from being cuboidal to being spindle-
shaped in a dose-dependent manner. The results obtained for 
the HSG cells were similar to those obtained for the HSY cells 
(data not shown).
Next, the proliferation of cancer cells treated with 0, 1, 2, 
5 and 10 mM of VPA was assessed by MTT assay. As shown 
in Fig. 2, VPA inhibited the proliferation of SGC cells in a 
dose-dependent manner. Treatment with 5 mM VPA induced 
a proliferation inhibition rate of ~40-70% in both cancer 
cell lines. Degenerated cancer cells were observed at a high 
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concentration (10 mM) of VPA. In particular, the HSY cells 
were most sensitive to the inhibitory effects of VPA on cell 
proliferation.
Antitumour effect of VPA on salivary gland tumours in vivo. 
Based on the in vitro findings discussed above, to investigate 
the antitumour effect of VPA on salivary gland tumours 
in vivo, experiments with salivary gland tumour xenografts 
were performed. HSY cells were inoculated subcutaneously 
into the back of nude mice (n=5), and oral VPA (0.2 and 0.4% 
w/v) administration in drinking water was initiated at 1 week 
after the inoculation. Control mice drank water without VPA. 
As shown in Fig. 3, VPA treatment significantly suppressed 
tumour growth compared with the growth observed in the 
untreated controls. However, there was no significant differ-
ence between the 0.2 and 0.4% VPA groups. In addition, all 
of the VPA-treated mice without inoculation of cancer cells 
showed weight loss due to drug toxicity (data not shown).
Effect of VPA on the cell cycle distribution of salivary gland 
cancer cells. We next investigated the effect of VPA on the 
cell cycle distribution of SGC cells to explore the underlying 
mechanism of VPA-mediated cell growth inhibition. Cancer 
cells treated with 2 and 5 mM of VPA were subjected to cell 
cycle analysis by flow cytometry. As shown in Fig. 4, VPA 
treatment effectively altered the cell cycle distribution of the 
Figure 1. Phase-contrast micrographs of HSY cells treated with VPA. HSY cells were treated with 0, 2 and 5 mM of VPA for 24 h. The morphology of HSY 
cells was transformed from being cuboidal to being spindle-shaped in a dose-dependent manner. Original magnification, x40.
Figure 2. Effects of VPA on SGC cell proliferation. Salivary gland cancer (SGC) cells were seeded at a concentration of 2x103 cells/well on 96-well plates. 
Twenty-four hours later, the cells were treated with various concentrations (0, 1, 2, 5 and 10 mM) of VPA for 2 and 4 days. In vitro cell proliferation was 
evaluated by the MTT assay. VPA inhibited the proliferation of SGC cells in a dose-dependent manner (A, HSY cells; B, HSG cells). Degenerated cancer cells 
were observed at a high concentration (10 mM) of VPA. *P<0.05, significant difference from the untreated control group.
Figure 3. Antitumour effects of VPA on tumour xenografts. HSY cells (5xl06 
cells) were inoculated subcutaneously into the back of nude mice. Once pal-
pable tumours were established at 1 week after the inoculation, VPA treatment 
was initiated by administering VPA (0, 0.2 and 0.4% w/v) in drinking water. 
Tumour volume and the body weight (data not shown) of mice were measured 
twice a week. The tumour volumes were calculated by the following formula: 
0.5 x largest diameter x (smallest diameter)2 in xenografted mice. For each 
treatment, 6 mice were used. VPA treatment significantly suppressed tumour 
growth relative to the growth observed for the untreated controls. However, 
there was no significant difference between the 0.2 and 0.4% VPA groups. 
*P<0.05, significant difference from the untreated control group.
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HSY cells. Compared to the controls showing 56.2% cells in 
the G1 phase at 24 h, VPA treatment at doses of 2 and 5 mM 
resulted in 60.4 (P<0.05) and 73.8% (P<0.05) cells in the G1 
phase of the cell cycle, respectively (Table I). The population 
of cells in the G1 phase was significantly increased in the VPA 
treatment group relative to the population in the untreated 
controls. Similar results were also observed for HSG cells 
(data not shown).
Mechanisms of the antitumour effect of VPA on salivary 
gland cancers. To further identify the mechanisms of the anti-
tumour effect on SGC by VPA treatment, the expression levels 
of tumour-suppressor genes p21 and p27 were examined by 
real-time RT-PCR. Fig. 5 shows the mRNA expression levels 
of p21 and p27 in HSY and HSG cells after 24 or 48 h of treat-
ment with 2 or 5 mM VPA. VPA markedly upregulated the 
levels of both p21 and p27 mRNA expression in both SGC cell 
lines. The expression of p21 and p27 mRNA was increased in 
a time-dependent manner. In particular, in HSY cells treated 
with 5 mM VPA, the mRNA expression levels of both p21 and 
p27 were increased appreciably.
Discussion
SGC frequently spreads to regional lymph nodes and distant 
organs and its prognosis is quite poor (1-6). Among the 
multiple options available for SGC treatment, surgical resec-
tion is currently the primary choice and standard option (5,6).
In addition, SGC shows low sensitivity to chemotherapy and 
radiotherapy, and the effectiveness of systemic chemotherapy 
against SGC has not been established. Therefore, it is apparent 
that the development of more effective chemotherapeutic drugs 
and strategies against SGC is necessary. Recent advance-
ments in the field of cancer epigenetics have shown that the 
development of cancer involves epigenetic abnormalities along 
with genetic alterations (9,10). Histone acetylation is one of 
Figure 4. Flow cytometric analysis of treatment with VPA in salivary gland cancer cells (HSY cells). Cancer cells treated with 2 and 5 mM of VPA were 
subjected to cell cycle analysis by flow cytometry. VPA treatment effectively altered the cell cycle distribution of salivary gland cancer cells. The population 
of cells in the G1 phase was significantly increased in the VPA treatment group relative to the population observed in the untreated controls. Similar results 
were also observed for HSG cells (data not shown). *P<0.05, significant difference from the untreated control group. 
Figure 5. Effects of VPA on the mRNA expression of p21 and p27 in salivary gland cancer cells. Cancer cells grown under subconfluent conditions were treated 
with VPA (0, 2 and 5 mM) for 24 or 48 h. The mRNA expression levels of p21 and p27 were examined by real-time RT-PCR. GAPDH was used as an internal 
control. The data are expressed as the ratio of the GAPDH-normalised fold-change in the PCR product in control cells. Experiments were performed at least 
three times. VPA markedly upregulated the levels of p21 and p27 mRNA expression in both salivary gland cancer cell lines (A, HSY cells; B, HSG cells). The 
results are representative of the means of three independent data. *P<0.05, significant difference from the untreated control group. 
Table I. Effect of VPA on cell cycle distribution of salivary 
gland cancer cells (HSY cells).
 VPA ---------------------------------------------------------------------------------
 2 mM 5 mM -------------------------------------- --------------------------------------
 Control (%) 12 h (%) 24 h (%) 12 h (%) 24 h (%)
G1 56.2±0.8 57.7±6.0 60.4±0.6a 67.1±1.6a 73.8±2.0a
G2 24.6±0.3 21.9±0.6 18.3±2.2a 21.2±0.1a 15.1±0.6a
aP<0.05, significant difference from the untreated control group.
  A   B
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these epigenetic changes and a regulator of gene expression; 
moreover, it plays an important role in carcinogenesis. Histone 
acetylation is associated with transcriptional activation and 
silencing and is regulated by a balance between the opposing 
activities of HAT and HDAC. The inactivation of HAT and 
activation of HDAC have been observed in various types of 
cancers (10). HDAC inhibitors have been reported to exhibit 
antitumour effects against various human tumour cells and, 
therefore, have become promising candidates for cancer 
treatment. Several HDAC inhibitors, such as vorinostat and 
depsipeptide, have undergone or are undergoing both phase I 
and phase II clinical trials as anticancer agents against haema-
tological malignancies and solid tumours (12,13). However, 
there is no reported study on the implementation of such 
inhibitors against salivary gland cancer.
VPA has recently been shown to exhibit activity as an 
HDAC inhibitor. VPA has also been reported to prevent the 
growth of many human cancers, including neuroblastoma, 
erythroleukaemia, acute myelogenous leukemia (11,12), 
osteosarcoma (25) and carcinomas of the breast (8), skin (16), 
prostate (26), lung (27) and colon (28), suggesting that it can be 
a useful agent for the treatment of a wide variety of malignan-
cies. In the head and neck region, the effect of VPA against 
squamous cell carcinomas has been reported (29); however, 
its effect against SGC has never been reported. Thus, in the 
present study, we investigated the antitumour effects of VPA 
against SGCs. It was clearly demonstrated that VPA inhibited 
the proliferation of SGC cells in vitro and that VPA treatment 
by oral administration effectively inhibited the growth of sali-
vary gland tumours in xenograft models in vivo. Furthermore, 
we observed that VPA induced cell cycle arrest in the G1 phase 
with the upregulation of p21 and p27 expression in SGC cells. 
Many researchers have investigated the underlying mecha-
nism of cancer cell growth inhibition induced by VPA acting 
as an HDAC inhibitor (7,8,19,25). Gottlicher et al (30) demon-
strated that VPA relieves HDAC-dependent transcriptional 
repression and induces the hyperacetylation of histones in 
several types of cancer cells in vitro, as well as reduced tumour 
growth and metastasis formation in animal experiments. The 
authors indicated that VPA is a powerful HDAC inhibitor and 
might serve as an effective drug for cancer therapy. On the 
other hand, Chen et al (31) reported that VPA inhibited the 
proliferation and invasion of bladder cancer cells by increasing 
histone H3 acetylation. In contrast to findings reported for 
bladder cancer, VPA had no effect on invasion or migration for 
prostate cancer cells. The authors concluded that VPA exerts 
its effect in a cancer type-specific manner. In the present study, 
VPA inhibited the proliferation of SGC cells in vitro and the 
growth of tumours formed by SGC cell inoculation. Although 
this antitumour effect of VPA against SGC is not fully under-
stood, VPA might be able to serve as an effective drug for the 
treatment of SGC, acting as an inhibitor of HDAC. 
To explore the underlying mechanism of VPA-mediated 
cancer cell growth inhibition, we examined the effect of VPA 
on the cell cycle phases and distribution of SGC cells treated 
with various concentrations of VPA. Our flow cytometric anal-
ysis data indicated that VPA induced the G1 arrest of the cell 
cycle progression in SGC cells in a time- and dose-dependent 
manner. Numerous reports have indicated that HDAC inhibi-
tors induce cell cycle arrest, differentiation and apoptosis in 
many cancer cells by decreasing the activity of HDAC and 
leading to the accumulation of histone hyperacetylation 
(7,11,14,15). VPA has also been reported to exert its antitu-
mour effects by inducing cell cycle arrest, differentiation and 
apoptosis of cancer cells. Greenblat et al (32) demonstrated 
that VPA activates Notch-1 signalling in human carcinoid 
tumour cells in vitro and in vivo, which results in the inhibi-
tion of cell growth via the induction of cell cycle arrest. VPA 
is also known to affect several different signalling pathways, 
including those of extracellular-regulated kinase (ERK)-
AP-1, protein kinase C (PKC), glycogen synthase kinase-3 β 
(GSK-3β) and Wnt. In addition, VPA has recently garnered 
attention as a specific inhibitor of HDAC activity (7,19). In the 
present study, we did not examine the molecular pathway of 
VPA against SGC; however, VPA may act as an effective drug 
for the treatment of SGC through these molecular pathways.
Furthermore, to explore the underlying mechanism of 
the VPA-mediated G1 arrest of cell cycle progression, we 
examined the expression levels of tumour-suppressor genes 
p21 and p27 in SGC cells treated with various concentrations 
of VPA by real-time RT-PCR. Our data indicated that VPA 
upregulated the expression of p21 and p27 in SGC cells in 
a time-and dose-dependent manner. The cell cycle progres-
sion in mammalian cells is controlled by protein complexes 
composed of cyclins and cyclin-dependent kinases (CDKs), 
although cell cycle regulation is complex (11,28). In prostate 
cancer cells, Sidana et al (34) demonstrated that VPA treat-
ment caused cell cycle arrest, as determined by the increase 
in p21 and p27 and decrease in cyclin D1 expression. p21, a 
cyclin-dependent kinase inhibitor, plays an important role in 
cell cycle progression and has been shown to be consistently 
induced by numerous HDAC inhibitors (11,28). It is well known 
that p21 is a transcriptional target of the tumour-suppressor 
gene p53 and a downstream effector of p53-dependent cell 
growth arrest. Induction of p21 expression may lead to the 
marked G1 arrest of cancer cells. In addition, p21 can also 
bind the proliferation cell nuclear antigen (PCNA), leading to 
an inhibition of DNA replication (33). We previously reported 
that a differentiation-inducing drug, vesnarinone, induced 
histone hyperacetylation and p21 gene expression, resulting 
in cell growth arrest in a human SGC cell line (24). In the 
present study, VPA induced G1 cell cycle arrest and upregu-
lated p21 expression in SGC cells, suggesting that VPA may 
induce histone hyperacetylation. On the other hand, p27 is a 
p21-related cyclin-dependent kinase inhibitor that regulates 
the progression of cells from the G1 to S phase in the cell cycle 
(28). Downregulation of p27 has been associated with cancer 
progression and unfavourable results with respect to several 
malignancies. It is well known that reduced expression of p27 
is frequently observed in various cancers, and a lack of p27 is 
suggested to be due to an enhancement in its degradation (13).
We previously reported that the upregulation of p27 protein 
may exert growth-inhibitory effects by inducing G1 arrest 
and apoptosis in oral cancer cell lines. p27 also modulates 
the cell cycle progression and apoptosis of cancer cells, but its 
contribution to HDAC inhibitor-induced processes remains to 
be fully elucidated.
In the animal experiments performed in the present study, 
we administered VPA at a concentration of 0.2 or 0.4% w/v 
in drinking water. VPA treatment markedly suppressed the 
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growth of salivary gland tumours when compared with the 
growth observed in the untreated controls, and there was no 
significant difference between the 0.2 and 0.4% VPA groups. 
Shabbeer et al (8) demonstrated that the administration of 
0.4% w/v VPA in drinking water was effective in inducing 
growth arrest, cell death, and senescence in vivo against pros-
tate cancer. Furthermore, the authors indicated that the mean 
plasma level of VPA in mice was 0.4 mM, which is approxi-
mately the level obtained in human patients on VPA. Although 
we did not measure the plasma level of VPA in mice, this VPA 
concentration (0.4% w/v) poses no significant risk for inducing 
toxic effects, including thrombocytopenia and somnolence.
In summary, the present study demonstrated the possibility 
of using a new and safe anticancer therapy against SGC, 
supporting the use of HDAC as a molecular target for the 
expression of tumour-suppressor genes, such as p21 and p27. 
We provide evidence that suggests that VPA could contribute 
to the development of more effective chemotherapy against 
SGC. Further studies are needed to characterise the antitu-
mour activity of VPA in vivo in other tumour types of SGC 
for clinical trials.
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